Codexis (CDXS) Projected to Post Earnings on Thursday

Codexis (NASDAQ:CDXS) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Codexis to post earnings of $0.01 per share and revenue of $35.8340 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Codexis Price Performance

Shares of NASDAQ:CDXS opened at $1.11 on Wednesday. The company has a market capitalization of $99.81 million, a P/E ratio of -1.45 and a beta of 2.47. The company’s 50-day moving average is $1.49 and its 200 day moving average is $2.02. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.02 and a current ratio of 4.12. Codexis has a fifty-two week low of $1.05 and a fifty-two week high of $4.30.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Wall Street Zen cut shares of Codexis from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Codexis in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of Codexis

Several hedge funds and other institutional investors have recently bought and sold shares of CDXS. State of Wyoming purchased a new position in shares of Codexis in the second quarter valued at about $25,000. Victory Capital Management Inc. purchased a new position in shares of Codexis in the 3rd quarter worth about $25,000. CIBC Bancorp USA Inc. bought a new position in Codexis in the 3rd quarter valued at approximately $26,000. BNP Paribas Financial Markets lifted its stake in Codexis by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,608 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 8,038 shares during the period. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Codexis in the 4th quarter worth $45,000. Hedge funds and other institutional investors own 78.54% of the company’s stock.

About Codexis

Codexis, Inc, headquartered in Redwood City, California, is a leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company’s proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability. By leveraging this technology, Codexis provides custom biocatalysts designed to improve manufacturing efficiency and reduce environmental impact.

Since its founding in 2002, Codexis has expanded its capabilities from early-stage research to commercial-scale production.